Biogen’s LEQEMBI® Gains FDA Approval for Once Every Four Weeks Maintenance Dosing in Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

January 27, 2025 | Monday | News
EU Approves Sarclisa in Combination with VRd for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

January 23, 2025 | Thursday | News
IMPACT Therapeutics' Senaparib Capsules Receive NMPA Approval for Maintenance Treatment of Advanced Ovarian Cancer in China

 IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...

January 20, 2025 | Monday | News
Silexion Therapeutics Prices Public Offering to Raise $5 Million for RNAi Cancer Therapy Development

Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA inter...

January 16, 2025 | Thursday | News
Incyte and Syndax Announce FDA Approval of Niktimvo™ for Chronic GVHD Treatment

 Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™...

January 16, 2025 | Thursday | News
Acadia Pharmaceuticals Submits Marketing Authorization Application for Trofinetide in the EU for Rett Syndrome Treatment

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the company has submitted a Marketing Authorization Application (MAA) to the European M...

January 15, 2025 | Wednesday | News
China Approves Sarclisa for Relapsed/Refractory Multiple Myeloma, Expanding Treatment Options

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethaso...

January 14, 2025 | Tuesday | News
Vertex Pharmaceuticals and Zai Lab Announce Exclusive Collaboration for Development and Commercialization of Povetacicept in Asia

-Vertex Pharmaceuticals Incorporated  and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...

January 13, 2025 | Monday | News
Bayer Submits Supplemental New Drug Application for KERENDIA® (Finerenone) to Treat Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone...

January 13, 2025 | Monday | News
Samsung Bioepis and Teva Forge Strategic Partnership for U.S. Launch of EPYSQLI® Biosimilar

Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the companies have entered into a license, developm...

January 13, 2025 | Monday | News
Xentria Expands Global Clinical Trials and Biosimilar Portfolio in 2025

Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical needs, announced operational expansion ...

January 09, 2025 | Thursday | News
Merck's GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) of China approv...

January 09, 2025 | Thursday | News
TC BioPharm Shareholders Approve 25% Stock Dividend, Reinforcing Strong Financial Outlook

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ...

January 07, 2025 | Tuesday | News
Spyre Therapeutics Grants Stock Options to Non-Executive Employee as Part of Equity Inducement Award

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineerin...

January 06, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close